Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) announced a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80, effective with the dividend payable on April 20, 2026 to shareholders of record on April 6, 2026.
The change raises the annual cash dividend to $3.44 per share and follows 15 consecutive years of dividend increases. The Board also authorized a $1 billion increase in the share repurchase program, added to approximately $0.4 billion available as of December 31, 2025.
Quest Diagnostics (NYSE: DGX) launched Quest Flow Cytometry MRD for Myeloma on Feb 2, 2026, an ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma.
The test reports sensitivity comparable to next-generation sequencing, five-day specimen stability versus three days for conventional flow, works without a pre-treatment baseline aspirate, and is promoted as lower cost to support broader access and clinical-trial monitoring.
Quest Diagnostics (NYSE: DGX) announced it was named to Fortune's 2026 World's Most Admired Companies list for the 12th consecutive year and ranked #2 in the "Health Care: Pharmacy and Other Services" industry category.
The recognition is based on nine corporate‑reputation attributes surveyed by Korn Ferry and Fortune, covering product quality, innovation, long‑term value, financial profile, responsibility, and people management. Quest highlighted its 55,000 colleagues and role delivering diagnostic insights from one of the largest de‑identified clinical lab databases, serving roughly one in three U.S. adults annually.
Sonora Quest Laboratories (NYSE:DGX) named Jennifer Erickson as Chief Executive Officer‑Elect, succeeding longtime CEO David Dexter, who will retire effective March 31, 2026. Dexter will work with Erickson starting Feb. 2, 2026 to complete a planned transition. Dexter led the company for more than 26 years, overseeing growth to a market‑share leadership position in Arizona and operations performing more than 100 million diagnostic tests per year. Erickson brings over 20 years of health‑care leadership and previously served as Sonora Quest CFO (1999–2004).
Quest Diagnostics (NYSE: DGX) will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026 before market open. The company will host a conference call at 8:30 a.m. Eastern Time the same day.
Dial-in details: 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with passcode 7895081. The earnings release and live webcast will be posted at www.QuestDiagnostics.com/investor. Participants are advised to dial in ~10 minutes early.
A replay will be available online at the investor site and by phone at 866-388-5361 (domestic) or 203-369-0416 (international) from ~10:30 a.m. ET on February 10, 2026 until midnight ET on February 24, 2026. Investors are encouraged to review the company’s periodic SEC filings, including risk factors.
Quest Diagnostics (NYSE: DGX) announced that data using its Haystack MRD® circulating tumor DNA test will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium, held January 8-10, 2026 in San Francisco and online.
Two poster presentations on January 10, 2026 (12:00 PM–1:30 PM PST) will report: 1) reproducibility and clinical concordance of a tumor-informed MRD assay in resected colorectal cancer from the DYNAMIC trials (Abstract 26; lead author Jeanne Tie) and 2) use of ctDNA to monitor patients undergoing total neoadjuvant treatment for locally advanced rectal adenocarcinoma (Abstract 30; lead author Eric Christenson).
Corewell Health and Quest Diagnostics (NYSE: DGX) completed a joint venture to form Diagnostic Lab of Michigan, LLC, with Quest owning 51% and Corewell owning 49%. The JV will expand access to laboratory services in Michigan and operate while existing labs continue to serve patients until a new 100,000-square-foot laboratory at Corewell Health Southfield Center opens in Q1 2027.
Quest has begun deploying its Collaborative Lab Solutions (Co-Lab) across all 21 Corewell hospitals, including supply chain, lab management, patient blood and anemia management, lab analytics and stewardship, and reference testing to support quality, innovation, access and productivity.
Quest Diagnostics (NYSE: DGX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 4:30 p.m. PT. Jim Davis, Chairman, CEO and President, and Sam Samad, EVP and CFO, will discuss the company’s strategy, performance, and market trends during a presentation and Q&A.
The session will be webcast live and available at ir.QuestDiagnostics.com; an archived webcast will be posted within 24 hours and will remain available through February 11, 2026.
Haystack Oncology (Quest Diagnostics NYSE: DGX) announced a research collaboration with Rutgers Cancer Institute and RWJBarnabas Health to evaluate Haystack MRD, a circulating tumor DNA (ctDNA) test, in a prospective phase II trial titled MRD-PORT (NCT06979661) to guide postoperative radiation and systemic therapy in stage II/III non-small cell lung cancer.
Key context: an April 2025 NEJM study found Haystack MRD identified clinical complete response at a median of 1.4 months vs >6 months by imaging, and the test received FDA Breakthrough Device Designation in August 2025.
Octave Bioscience announced a strategic collaboration with Quest Diagnostics (NYSE: DGX) to make the Octave® Multiple Sclerosis Disease Activity (MSDA) Test available through Quest’s approximately 7,000 U.S. patient service centers and in-office phlebotomists starting December 1, 2025.
The MSDA Test measures 18 validated protein biomarkers, is described as clinically and analytically validated, is reimbursed by multiple payers, and is supported by a patient affordability program. Quest also has first rights to consider providing specimen collection for future Octave tests. The MSDA Test is performed in Octave’s CLIA/CAP/CLEP-certified Menlo Park laboratory.